VA-REGULA-FORENSICS
8.6.2021 14:02:08 CEST | Business Wire | Press release
Permission.io, the digital advertising platform that lets online marketers reward users for interacting with ads, announces the integration with the Regula Document Reader SDK to cover the full know-your-customer (KYC) process. The partnership mitigates the risk of fraud and delivers a verified audience to advertisers.
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. With 28 years of experience, Regula is a trusted name to experts in both the private and public sectors worldwide. The company has the industry’s largest database of document templates and uses artificial intelligence to automatically determine document type and reveal the visual signs of fraud. Proprietary Face Matching and Liveness Detection technologies make Regula a one-stop solution for identity verification.
Permission.io is a digital advertising platform that enables consumers to earn rewards for interacting with advertisements. The company uses blockchain technology to allow advertisers to reward consumers with ASK, the platform’s native digital currency, for signing up, providing profile and preference data, engaging with video ads, referring friends, and other activities.
“Digital Advertising is ripe for a change,” said Charles Silver, CEO of Permission.io . “Big tech exploits user data, and click fraud is estimated to grow into an $87 billion business in 2021. The major platforms grade their own homework, so to speak, and advertisers are getting the short end of the stick. Too often, the ads they pay to deliver are not even being seen. Permission is bringing the change this industry needs by respecting user data and by delivering to advertisers superior targeting and better ROI on their considerable spend.”
“Financial technology needs the most secure protection from fraud, and we’re happy to share our expertise in document forensics with emerging industry leaders to ensure clear and reliable fraud detection while onboarding and asset management,” said Arif Mamedov, President of Regula Forensics Inc . “Our web and mobile products have been designed to meet the requirements of fintech and to be seamlessly integrable into any scenario and interface.”
Regula Document Reader SDK parses documents and extracts personal data, eliminating manual data input and minimizing mistakes. When it comes to data validation, Regula’s technology cross-checks the data obtained from MRZ, VIZ, and barcodes. The process of user identification is completed with face matching in seconds, while the personal data is secured by the internal Permission network. “We are very excited to add Regula's invaluable expertise to our promise to prevent identity fraud and deliver a delightful user experience,” Silver said.
About Regula Forensics:
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. Regula’s software product suite includes ID verification, facematching and liveness technologies for mobile applications and web-based solutions, to build a seamless on-premises digital identity and biometric verification workflow.
135 international borders are equipped with Regula hardware and software products. Regula is an official partner of the UN, Interpol, OSCE, IATA and ICAO. For more information, visit https://mobile.regulaforensics.com .
About Permission.io:
Permission.io is the leading platform for permission advertising for eCommerce. The company has created the ASK digital currency to enable individuals to securely grant permission and monetize their data on Permission.io and 3rd-party e-commerce platforms. Advertisers reward consumers with ASK for interacting with brands and content, building trust, and increasing ROI. To learn more, visit https://permission.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005012/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom